文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克患者糖皮质激素处方实践差异

Variation in Corticosteroid Prescribing Practices for Patients With Septic Shock.
PubMed 文献 · Crit Care Explor · 2025-02-21
一句话结论在血管活性药依赖性脓毒性休克患者中,糖皮质激素使用差异16.5%归因于ICU、10.1%归因于医生,提示需多层面干预标准化实践。

本研究为回顾性队列研究,利用美国9家医院26个ICU的电子健康记录,纳入2018至2020年收治的脓毒性休克ICU患者,以血管活性药启动后2天内是否使用糖皮质激素为指标,通过医师电子签名链接患者与主治医师,并拟合分层混合效应逻辑回归模型分析糖皮质激素使用的相关因素及医师和ICU层面的变异。结果显示,5322例血管活性药依赖性脓毒性休克患者中1294例(24.3%)在血管活性药启动后2天内使用糖皮质激素;ICU层面使用中位数为21.8%(IQR 18.5-25.7%),医师层面中位数为22.0%(IQR 11.9-32.7%);控制患者和医师特征后,16.5%的变异归因于ICU,10.1%归因于医师。结论认为ICU和医师均贡献了糖皮质激素使用的变异,强调需要多层面干预以标准化重症监护中的循证实践。

要点

  • 5322例血管活性药依赖性脓毒性休克患者中,1294例(24.3%)在血管活性药启动后2天内接受了糖皮质激素治疗。
  • ICU层面糖皮质激素使用中位数为21.8%(IQR 18.5-25.7%),医师层面中位数为22.0%(IQR 11.9-32.7%)。
  • 控制患者和医师特征后,糖皮质激素给药的变异中16.5%归因于ICU,10.1%归因于医师。
  • 作者认为ICU和医师均贡献了糖皮质激素使用的变异,强调需要多层面干预以标准化重症监护中的循证实践。

适用人群与场景

  • 2018至2020年间收治于美国9家医院26个ICU的脓毒性休克患者。
  • 血管活性药依赖性脓毒性休克患者。

研究设计与关键结果

  • 研究类型:回顾性队列研究,使用多医院健康系统电子健康记录。
  • 样本量:5322例血管活性药依赖性脓毒性休克患者,链接至26个ICU的174名主治医师。
  • 主要结局:1294例(24.3%)在血管活性药启动后2天内接受糖皮质激素治疗。
  • ICU层面糖皮质激素使用中位数21.8%(IQR 18.5-25.7%);医师层面中位数22.0%(IQR 11.9-32.7%)。
  • 混合效应回归控制患者和医师特征后,糖皮质激素给药的变异中16.5%归因于ICU,10.1%归因于医师。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为ICU和医师均贡献了糖皮质激素使用的变异,强调需要多层面干预以标准化重症监护中的循证实践。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Understanding sources of variation in acute care delivery may inform targeted strategies to promote evidence-uptake. We sought to characterize physician-level and ICU-level variation in corticosteroid prescribing for patients with septic shock.

DESIGN: We performed a retrospective cohort study using the electronic health record of a multihospital health system. We identified ICU patients with septic shock admitted between 2018 and 2020. Using medication administration data, we determined which patients received corticosteroids within 2 days of vasopressor initiation. We linked each patient to their attending physician of record using digital signatures from clinical documentation. We then fit a hierarchical mixed-effects logistic regression model to identify factors associated with corticosteroid use and quantify variation in corticosteroid administration across physicians and ICUs.

SETTING: Twenty-six ICUs across nine hospitals in the United States.

PATIENTS: ICU patients with septic shock.

MEASUREMENTS AND MAIN RESULTS: Of 5322 patients with vasopressor dependent septic shock, 1294 (24.3%) were treated with corticosteroids within 2 days of vasopressor initiation. We linked these patients to 174 unique attending physicians across 26 ICUs. At the ICU-level, median corticosteroid use was 21.8% (interquartile range [IQR], 18.5-25.7%). At the physician-level, median corticosteroid use was 22.0% (IQR, 11.9-32.7%). In the mixed-effects regression controlling for patient and physician characteristics, 16.5% of the variation in corticosteroid administration was attributable to the ICUs and 10.1% was attributable to the physicians.

CONCLUSIONS: Both ICUs and physicians contribute to observed variation in the use of corticosteroids for vasopressor dependent septic shock. These findings underscore the need for multilevel interventions to standardize evidence-based practices in critical care.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Soni K, Minturn JS, Davis BS, et al. Variation in Corticosteroid Prescribing Practices for Patients With Septic Shock. Crit Care Explor. 2025. PMID: 39982133. doi:10.1097/CCE.0000000000001196

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。